A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
PUMA-ALI-4201 is a Phase 2 study evaluating alisertib monotherapy in patients with pathologically-confirmed small cell lung cancer (SCLC) following progression on or after treatment with one platinum-based chemotherapy and anti-PD-L1/PD-1 immunotherapy agent. Up to one additional systemic anti-cancer therapy for SCLC is allowed, for a total of up to two prior treatment regimens. This study is intended to identify the biomarker-defined subgroup(s) that may benefit most from alisertib treatment and to evaluate the efficacy, safety, and pharmacokinetics of alisertib.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek co najmniej 18 lat
- •Potwierdzony rozpoznaniem raka płuca z małymi komórkami
- •Poprzednia chemioterapia zawierająca sole platyny oraz immunoterapia
- •Możliwość włączenia do pięciu wcześniejszych sposobów leczenia
✗ Disqualifies
- •Poprzednia terapia innymi lekami skierowanymi na białko AURKA lub lekami typu Aurora-targeted, w tym alisertib
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- August 17, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (30)
Southern Cancer Center
Daphne, United States
The Oncology Institute of Hope and Innovation
Long Beach, United States
Rocky Mountain Cancer Centers
Lone Tree, United States
Georgetown Lombardi Cancer Center
Washington D.C., United States
Clermont Oncology Center
Clermont, United States
The Oncology Institute of Hope and Innovation
Fort Lauderdale, United States
Moffitt Cancer Center
Tampa, United States
Illinois Cancer Specialists
Niles, United States
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
Indianapolis, United States
University of Maryland Greenebaum Comprehensive Cancer Center
Baltimore, United States
Beth Israel Deaconess Medical Center
Boston, United States
Dana Farber Cancer Institute
Boston, United States
Henry Ford Hospital
Detroit, United States
Minnesota Oncology Hematology
Burnsville, United States
Nebraska Cancer Specialists
Grand Island, United States
Oncology Hematology Care Clinical Trials
Cincinnati, United States
University Hospital - Cleveland Medical Center
Cleveland, United States
Cleveland Clinic
Cleveland, United States
Zangmeister Cancer Center
Columbus, United States
Oncology Associates of Oregon
Eugene, United States
UPMC Hillman Cancer Center
Pittsburgh, United States
Medical University of South Carolina Hollings Cancer Center
Charleston, United States
SCRI Oncology Partners
Nashville, United States
Texas Oncology-Baylor Charles A. Sammons Cancer Center
Dallas, United States
University of Texas Southwestern Medical Center
Dallas, United States
Oncology & Hematology Associates of Southwest Virginia
Blacksburg, United States
Universtity of Virginia Health System
Charlottesville, United States
Virginia Cancer Specialists Research Institute
Fairfax, United States
Northwest Cancer Specialists
Vancouver, United States
Marshfield Medical Center
Marshfield, United States
Trial contact
Puma Biotechnology, Inc. Clinical Operations Senior Director
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/18/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.